A new partnership between a Danish and a British startup will lead the way for advancing patient access to medical psychedelics in Europe.
Little Green Pharma has been granted a licence to supply psilocybin from the Western Australia Government Department of Health.
Novel analogues of the psychedelic compound 5-MeO-DMT have shown demonstrable safety in preclinical results.
The first-ever authorised export of GMP-compliant natural psilocybin into the US has been completed.
Mindset Pharma says its next-generation psilocybin compounds could change the paradigm of microdosing by limiting the psychedelic effect.
Tryp Therapeutics has completed psychotherapy training for its upcoming Phase 2a psilocybin clinical trial.
PharmaDrug Inc.
Braxia Scientific will be carrying out a landmark clinical trial investigating multiple-dose psilocybin for treatment-resistant depression.
A psychedelic medicine startup will be developing a transdermal patch for sustained delivery of psilocin.
People will now be able to participate in psychedelic-assisted therapy in a group setting as the Institute for Integrative Therapies expands its services to support the...
